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Rezumat
 Efi cacitatea chimio- sau antibioterapiei endolimfatice indirecte, enterosorbţiei, stimulării drenului 
limfatic este net superioară metodelor obişnuite în lichidarea semnelor clinice de bază, obţinerea efectelor 
curative constatate radiologic, bacteriologic şi endoscopic. În bronhopneumopatiile nespecifi ce la copii 
şi adulţi metodele menţionate demonstrează efi cacitatea curativă înaltă, asigurând scurtarea timpului 
medicaţiei şi micşorarea dozelor necesare de preparate antibacteriene, corticoizi şi dezintoxicante. 
Summary
 The effi ciency of applying modifi ed medical courses which included injections of Izoniazid 
and streptomycin (canamycin) by methods of indirect endolymphatic (lymphotropic) therapy: general 
(LT) or regional (RLT), was investigated. It was shown that sanation of lymphatic system by means 
of LT or RLT in skin, lymphatical nodules, disseminated, infi ltrative lung tuberculosis signifi cantly 
accelerates elimination of basic clinical symptoms. Roentgenological, endoscopic, bacteriological 
results exceeded signifi cantly those of control. In nonTB lung diseases the lymphological complex is 
highly effective then usual treatment. 
EFFICACY OF PROSPAN HERBAL DROPS IN THE TREATMENT OF 
EXACERBATION OF CHRONIC BRONCHITIS
Sergiu Matcovschi, professor, Chair of Internal Medicine nr. 5, Angela Tcaciuc, 
“Nicolae Testemitanu” State University of Medicine and Pharmacy, Irina Matcovschi, 
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Arzneimittel
 In the exacerbation of chronic bronchitis the volume, purulence, viscosity and adhesion of 
sputum increase and patients frequently have diffi culty in expectorating. Mucolytic and expectorant 
agents change physiochemical properties of sputum to make it easier to clear [4, 5].
The aim of the present study was to investigate the changes of clinical symptoms and the tolerability 
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of an original ivy product – Prospan Herbal Drops (Engelhard Arzneimittel GmbH & Co. KG), given 
for the treatment of exacerbation of chronic bronchitis.
Patients and methods
 We investigated the short-term (10 days) infl uence of Prospan Herbal Drops on the clinical 
symptoms and tolerability of this drug in 42 patients aged from 37 to 68 years who suffered from 
exacerbation of chronic bronchitis (with or without obstruction), which were included in group 1 
(the essential group). Data obtained were compared with the data of the control group (group 2), 
which included 32 patients aged from 36 to 70 years, who also suffered with exacerbation of chronic 
bronchitis. The patient’s characteristics groups are shown in table 1. 
Table 1
 Basic demographic and medical data at onset of treatment
Group 1 Group 2
Number of patients 41 32
Female 6 5
Male 35 27
The ratio female/male 0,17 0,16
Mean age in years 53±1,3 52±1,1 p>0,5
Diagnosis: chronic obstructive bronchitis





The ratio obstructive bronchitis
 bronchitis without obstruction 1,3 1,3
Age of disease 6±2,1 5±2,6 p>0,5
 The data presented in table 1 demonstrated that the groups were comparable by sex and age 
of patients, diagnosis and age of disease. 
 During a scheduled observational period of 10 days, the patients in group 1 had to take 20 
drops of Prospan Herbal Drops 3 times/day according to the manufacturer’s dosing recommendations. 
The patients in group 2 did not have to take Prospan Herbal Drops. All the patients (group 1 and group 
2) also received Amoxicilline in a dose 500 – 1000 mg 3 times/day orally and patients with chronic 
obstructive bronchitis used Salbutamol – inhalation 1 – 2 puffs 3 times/day.
 Treatment success was assessed by observing the changes in the symptoms of bronchitis.
 The quantitative estimation of symptoms of bronchitis was done according to a scale, suggested 
by Lursac B. et al. [2] and modifi ed by us, the scale varies from 0 to 3 points.
Tolerability of Prospan Herbal Drops was evaluated by analysing adverse events.
Table 2















sputum is expectorated easy
sputum is expectorated hardly















at the high physical exertion
at the middle physical exertion
at the little physical exertion or at the rest
Results and discussion
The groups of the investigated patients were comparable concerning severity of essential 
symptoms of chronic bronchitis (Fig. 1). The difference between a middle value of the index which 
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Fig. 1. The symptoms before the treatment
The severity of cough signifi cantly decreased (p<0,001) in the both groups but in the bigger 
measure it decreased in group 1 (Fig. 2). The average value of cough severity index at 5th and 10th day 
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Points
Group 1 Group 2
Fig. 3. Dynamics of expectoration
 The same thing was observed in the dynamics of expectoration (Fig.3). The average value of 
index which characterised the expectoration was signifi cantly less in group 1 than in group 2, both at 
the 5th  (p<0,001) and the 10th day (p<0,001) of the treatment.
 Prospan Herbal Drops didn’t infl uence quality of sputum (Tab. 3). The average value of index 
which characterised quality of sputum was before the treatment 2,1±0,5 (here and afterwards: average 
value ± standard error) and 2,1±0,05 (p>0,5) in group 1 and 2 respectively, at the 5th day of the 
treatment remained almost unchanged – 2,1±0,5 and 2,1±0,05 (p>0,5), and at the 10th day of the 
treatment it was improved (p<0,002) in both groups in the same measure – 1,9±0,03 and 1,9±0,04 
(p>0,5), respectively. Dyspnoea decreased on the basis of the treatment that can be explained by the 
action of bronchodilatator and is not a action of Prospan Herbal Drops, because the dyspnoea severity 
index decreased (p<0,001) in both groups in the same proportion, being the following in groups 1 
and 2 respectively: initially 2,1±0,6 and 2,1±0,06 (p>0,5), at the 5th day of treatment – 1,5±0,12 and 
1,5±0,12 (p>0,5) and at the 10th day of the treatment – 1,1±0,06 and 1,1±0,06 (p>0,5) respectively. 
 Prospan Herbal Drops didn’t infl uence quality of sputum. The index middle value which is 
characterised quality of sputum was equal in group 1 and 2 (Tab. 3), at the 5th day of the treatment and 
remained almost unchanged, but at the 10th day of the treatment were improved in the both groups in 
the same measure. Dyspnoea decreased on the basis of the treatment and it can be explained by the 
action of bronchodilatator and is not an action of the Prospan Herbal Drops, because the dyspnoea 
severity index decreased in both groups in the same measure.
Table 3
The qualitative estimation of sputum in the treatment with Prospan Herbal drops of 
exacerbation of chronic bronchitis























* – signifi cant difference (p<0,001) in comparison with the initial index.
§ – signifi cant difference (p<0,002) in comparison with the initial index.
 All the patients tolerated Prospan Herbal Drops well. No adverse effects were observed in our 
patients. 
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 Our results correspond to the data of other authors [1, 3] and demonstrate that Prospan Herbal 
Drops has a benefi cial action on the exacerbation of chronic bronchitis and improves the symptoms 
of the disease.
Conclusions
Prospan Herbal Drops is an effi cient remedy for the treatment of the exacerbation of chronic 
bronchitis and contributes to a considerable improvement of the disease symptoms and all the patients 
tolerate it well.
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Summary
 The aim of the present study was to investigate the changes of clinical symptoms and the 
tolerability of an original ivy product – Prospan Herbal Drops (Engelhard Arzneimittel GmbH & Co. 
KG), given for the treatment of exacerbation of chronic bronchitis. We investigated the short-term 
(10 days) infl uence of Prospan Herbal Drops on the clinical symptoms and tolerability of this drug in 
42 patients aged from 37 to 68 years who suffered from exacerbation of chronic bronchitis (with or 
without obstruction). The results demonstrate that Prospan Herbal Drops has a benefi cial action on 
the exacerbation of chronic bronchitis, considerable improves the symptoms of the disease and all the 
patients tolerate it well.
Rezumat
Scopul acestui studiu a fost de a cerceta modifi cările simptomelor clinice şi tolerarea 
medicamentului natural ce conţine extract din frunze de iederă – Prospan Herbal Drops, care a fost 
utilizat în tratamentul exacerbărilor bronşitelor cronice. A fost investigată infl uenţa administrării de 
scurtă durată (10 zile) a preparatului Prospan Herbal Drops asupra simptomelor clinice şi tolerarea 
acestui medicament la 42 de pacienţi cu exacerbarea bronşitei cronice (cu sau fără obstrucţie) vârsta 
lor fi ind între 37 şi 68 de ani. Rezultatele studiului au demonstrat că Prospan Herbal Drops a avut 
un efect benefi c în bronşitele cronice, îmbunătăţind considerabil simptomele acestei maladii şi că toţi 
pacienţii au tolerat medicamentul bine.
 
